Fzata, Inc. Receives Significant NIH Grant for IBS Treatment
Fzata, Inc. is excited to share that it has received a generous five-year grant from the National Institutes of Health (NIH), amounting to up to $7 million, along with valuable in-kind contributions. This UG3/UH3 non-dilutive grant is focused on supporting the development of their groundbreaking drug candidate, BioPYM™ FZ006, which specifically aims to address chronic visceral pain linked to inflammatory bowel syndrome (IBS).
Essential Aspects of the NIH Grant
The NIH National Institute of Neurological Disorders and Stroke (NINDS) will fund crucial studies needed to push FZ006 toward being a leading treatment option for IBS. The grant will support various important processes, including IND-enabling studies, GLP toxicology evaluations, cGMP manufacturing, and the planning and implementation of Phase 1 clinical trials.
Dr. Zhiyong Yang's Perspective
Dr. Zhiyong Yang, the President and CEO of Fzata, expressed his thoughts on the importance of this funding, saying, "Chronic visceral pain related to IBS is a significant unmet healthcare challenge impacting many people. Around 10 to 15 percent of the American population suffers from severe pain with limited treatment options. Current opioid treatments carry risks of addiction, creating a pressing need for a safe, non-addictive alternative. With FZ006, we aim to become the leading option for effectively managing chronic abdominal pain. We look forward to partnering with our skilled team at UMB and NINDS to make a real difference for IBS patients and their families."
Collaboration with Academic Partners
Fzata's partnership with the University of Maryland, Baltimore (UMB) is a critical advancement in this project. Phil Robilotto, DO, MBA, from UMB, highlighted the significance of this collaboration by stating, "This NIH award presents an extraordinary opportunity for Fzata, a notable startup in UMB’s portfolio. The work funded by this grant will harness the insights and resources from UMB's scientific community to enhance Fzata's innovative technology in addressing major medical needs." He also pointed out the exciting developments concerning their pipeline, including another drug candidate, FZ002, which targets C. difficile infections and is set to start human clinical trials soon.
The Future of Therapeutics with BioPYM™
About Fzata, Inc.: The company has developed a cutting-edge therapeutics platform called Bioengineered Probiotic Yeast Medicines, or BioPYM™, committed to producing oral live biotherapeutics. This innovative platform enables probiotic yeast to function as a micro-factory in the gut, creating therapeutic agents where they are most needed. Through BioPYM™, Fzata is actively working on a range of proprietary drug candidates to address various gastrointestinal diseases and related disorders.
Further Information and Opportunities
If you’re interested in Fzata, Inc.'s groundbreaking work or are looking to explore potential collaborations, you can find more information on their official website. The company is also open to inquiries about investment opportunities and partnerships in this dynamic field.
For any questions or to discuss possible collaborations, you can contact Elizabeth Smith, PhD, MBA, the Chief Business Officer at Fzata. She is available via email for direct communication.
Frequently Asked Questions
What is the purpose of the NIH grant awarded to Fzata, Inc.?
The NIH grant aims to support the development of FZ006, a drug candidate focused on treating chronic visceral pain linked to IBS.
What are the key components of the research funded by the NIH?
The grant will finance IND-enabling studies, GLP toxicology, cGMP manufacturing, and the design of Phase 1 clinical trials.
Who is leading Fzata, Inc.?
Dr. Zhiyong Yang serves as the President and CEO of Fzata, Inc., guiding the company’s strategic initiatives.
What is BioPYM™?
BioPYM™ is an advanced therapeutics platform created by Fzata, utilizing probiotic yeast to produce live biotherapeutics directly in the gut.
How can interested parties learn more about Fzata's initiatives?
For more details, you can visit Fzata’s official website, which provides information about their projects and collaboration opportunities.
